000 | 01997 a2200577 4500 | ||
---|---|---|---|
005 | 20250515181553.0 | ||
264 | 0 | _c20091015 | |
008 | 200910s 0 0 eng d | ||
022 | _a1528-4336 | ||
024 | 7 |
_a10.1310/hct1003-143 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aWohl, D A | |
245 | 0 | 0 |
_aLow rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. _h[electronic resource] |
260 |
_bHIV clinical trials _c |
||
300 |
_a143-52 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xdrug therapy |
650 | 0 | 4 |
_aAcquired Immunodeficiency Syndrome _xdrug therapy |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAntiretroviral Therapy, Highly Active |
650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
650 | 0 | 4 | _aCD4 Lymphocyte Count |
650 | 0 | 4 |
_aCytomegalovirus _xgenetics |
650 | 0 | 4 |
_aCytomegalovirus Infections _xdrug therapy |
650 | 0 | 4 | _aDouble-Blind Method |
650 | 0 | 4 |
_aGanciclovir _xadministration & dosage |
650 | 0 | 4 |
_aHIV Infections _xcomplications |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aPolymerase Chain Reaction |
650 | 0 | 4 | _aProportional Hazards Models |
650 | 0 | 4 | _aValganciclovir |
650 | 0 | 4 |
_aViremia _xdrug therapy |
700 | 1 | _aKendall, M A | |
700 | 1 | _aAndersen, J | |
700 | 1 | _aCrumpacker, C | |
700 | 1 | _aSpector, S A | |
700 | 1 | _aFeinberg, J | |
700 | 1 | _aAlston-Smith, B | |
700 | 1 | _aOwens, S | |
700 | 1 | _aChafey, S | |
700 | 1 | _aMarco, M | |
700 | 1 | _aMaxwell, S | |
700 | 1 | _aLurain, N | |
700 | 1 | _aJabs, D | |
700 | 1 | _aBenson, C | |
700 | 1 | _aKeiser, P | |
700 | 1 | _aJacobson, M A | |
773 | 0 |
_tHIV clinical trials _gvol. 10 _gno. 3 _gp. 143-52 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1310/hct1003-143 _zAvailable from publisher's website |
999 |
_c19041208 _d19041208 |